In vitro and in vivo modifications of recombinant and human IgG antibodies
about
Posttranslational Modifications and the Immunogenicity of BiotherapeuticsHuman IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activationProtein catalyzed capture agents with tailored performance for in vitro and in vivo applications.Time-Dependent Structural Alteration of Rituximab Analyzed by LC/TOF-MS after a Systemic Administration to Rats.Two-dimensional capillary zone electrophoresis-mass spectrometry for the characterization of intact monoclonal antibody charge variants, including deamidation products.Impact of IgG Fc-Oligosaccharides on Recombinant Monoclonal Antibody Structure, Stability, Safety, and Efficacy.Forced degradation studies: current trends and future perspectives for protein-based therapeutics.Impact of cell culture on recombinant monoclonal antibody product heterogeneity.Charge heterogeneity: Basic antibody charge variants with increased binding to Fc receptors.Mass Spectrometry Based Mechanistic Insights into Formation of Tris Conjugates: Implications on Protein Biopharmaceutics.Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques.A chemical and computational approach to comprehensive glycation characterization on antibodies.Investigation of the interactions of critical scale-up parameters (pH, pO2 and pCO2) on CHO batch performance and critical quality attributes.Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab).Optimization of capillary zone electrophoresis for charge heterogeneity testing of biopharmaceuticals using enhanced method development principles.Database-independent Protein Sequencing (DiPS) Enables Full-length de Novo Protein and Antibody Sequence Determination.Microheterogeneity of Recombinant Antibodies: Analytics and Functional Impact.Targeting IgG in Arthritis: Disease Pathways and Therapeutic Avenues.Analytical comparability study of recombinant monoclonal antibody therapeutics.Forced degradation of recombinant monoclonal antibodies: A practical guide.Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies
P2860
Q26748614-2C79054C-C616-4C80-8E6B-7E12A739C9D5Q30360964-7688BB1A-F795-46A0-ABDD-2B47658BEF6BQ36107567-149BC1A7-AE51-4D4D-B5E3-67970DC54F35Q36239584-326F3A8A-2CA4-4CEE-8E52-9CD84744C717Q38628030-63534722-C054-45C0-AFEF-B7A7F1039DCDQ38762019-4F0E41B7-D4C4-4BF9-B839-C856E047F41EQ38855242-81AA35C8-BFB7-4A5C-90D5-63C559DE938EQ38907094-847336AE-1CD1-4AEC-A00C-CE82559F3038Q39454978-3940DD7C-C198-4CF5-9D92-277979CAE55EQ39527935-ECCD4ABC-0134-4E96-B644-30AFC5035B8CQ39711072-0297065A-5BEF-471C-AE29-F2FC2C79BAC6Q42002222-9411CC27-7C2E-40AB-B457-7CB021E0CEC7Q42071492-3E6DADEA-EB82-47B2-9D49-06691158FBDDQ42113781-EB8FFD9D-F930-4597-81F3-61FD692384BAQ47830126-287B7D50-05B4-49AD-B076-81BAD82AAF4AQ47913256-57E2E236-FE14-4F67-ADEF-9A640B43D580Q50237001-6A558128-5F14-47F4-BDA9-77FCDBDCC1F4Q52370705-4AB8E4AB-055B-47CB-A7F9-6DAB04BBF05CQ52669512-8E0028BA-60D3-40AA-9656-1D689B354053Q53090989-DEE42E7B-B7EE-4DE7-B6C2-30CFEA368C70Q58572618-A0459BFC-2134-4653-ABD9-44024CBA55C1
P2860
In vitro and in vivo modifications of recombinant and human IgG antibodies
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
In vitro and in vivo modifications of recombinant and human IgG antibodies
@ast
In vitro and in vivo modifications of recombinant and human IgG antibodies
@en
In vitro and in vivo modifications of recombinant and human IgG antibodies
@nl
type
label
In vitro and in vivo modifications of recombinant and human IgG antibodies
@ast
In vitro and in vivo modifications of recombinant and human IgG antibodies
@en
In vitro and in vivo modifications of recombinant and human IgG antibodies
@nl
prefLabel
In vitro and in vivo modifications of recombinant and human IgG antibodies
@ast
In vitro and in vivo modifications of recombinant and human IgG antibodies
@en
In vitro and in vivo modifications of recombinant and human IgG antibodies
@nl
P2093
P2860
P3181
P356
P1476
In vitro and in vivo modifications of recombinant and human IgG antibodies
@en
P2093
Adriana Z Kita
Alyssa Neill
Bruce Andrien
Christine Nowak
Gomathinayagam Ponniah
Guilong Cheng
Hongcheng Liu
Hui-Min Zhang
Nidia Gonzalez-Lopez
Rekha Patel
P2860
P304
P3181
P356
10.4161/MABS.29883
P407
P577
2014-01-01T00:00:00Z